CD70 and acute myeloid leukemia: Reports have identified CD70 expression in 45% of AML blasts and in 30% of LSCs,276 or even lower.277 Other studies suggest its expression in up to 75% of AML LSCs.199 The targeting of CD70 with a mAb (cusatuzumab) has been demonstrated to successfully eliminate AML-LSCs when combined with HMAs, making it an exciting target for CAR-T cell therapy.278 The preclinical evidence for CAR-T cells targeting CD70 is encouraging.277,279